News! The nanotechnology-based cancer diagnostics-development company known as Senior Scientific is now Imagion Biosystems. The company has spun out from its previous parent and has a new Board of Directors and new investors but carries forward the intellectual assets, scientific collaborations, and clinical goals of Senior Scientific. The restructuring and new capital will help the company drive development of our MagSense® diagnostic imaging technology towards clinical use.
The first word of our new name, “Imagion,” is a portmanteau of “imaging” and Magnetic Iron Oxide Nanoparticles (known as “ION”s), which are at the core of our technology. The name reflects the innovative thinking and optimism of all of us here at Imagion Biosystems as we develop the clinical potential of magnetic relaxometry imaging for earlier cancer diagnosis and better human health.
Positive Results Received from WSU on MagSense® Dosage – Phase 2 Clinical Trial on HER2 Breast Cancer Imaging Agent
FDA Submission of IND for MagSense® HER2 Phase 2 Clinical Trial on Track Q4 2025 Key Highlights: Wayne State University Collaboration Program Delivers Positive and
